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Abstract
The incidence of head and neck squamous cell carcinoma (HNSCC) has been gradually increasing
over the last three decades. Recent data have now attributed a viral aetiology to a subset of head
and neck cancers. Several studies indicate that oral human papillomavirus (HPV) infection is likely
to be sexually acquired. The dominance of HPV 16 in HPV+ HNSCC is even greater than that seen
in cervical carcinoma of total worldwide cases. Strong evidence suggests that HPV+ status is an
important prognostic factor associated with a favourable outcome in head and neck cancers.
Approximately 30 to 40% of HNSCC patients with present with early stage I/II disease. These
patients are treated with curative intent using single modality treatments either radiation or
surgery alone. A non-operative approach is favored for patients in which surgery followed by either
radiation alone or radiochemotherapy may lead to severe functional impairment. Cetuximab, a
humanized mouse anti-EGFR IgG1 monoclonal antibody, improved locoregional control and overall
survival in combination with radiotherapy in locally advanced tumours but at the cost of some
increased cardiac morbidity and mortality.
Finally, the improved prognosis and treatment responses to chemotherapy and radiotherapy by
HPV+ tumours may suggest that HPV status detection is required to better plan and individualize
patient treatment regimes.
Introduction and epidemiology
Cancer of the head and neck, includes all cancers arising
from the upper aerodigestive tract, and typically refers to
squamous cell carcinomas of the head and neck, which
are the predominant group. The incidence of head and
neck squamous cell carcinoma (HNSCC) has been gradu-
ally increasing over the last 3 decades. It is the 5th leading
cause of cancer by incidence and the 6th leading cause of
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cancer mortality in the world. In 2002, approximately
405,000 were reported and 211,000 deaths occurred
worldwide [1]. It is likely that approximately 500,000
cases worldwide will arise this year, and that only 40-50%
will survive for 5 years [2-4]. The typical case presents late,
as advanced metastatic cancer, and accounts for the poor
mortality rate. The most important risk factors so far iden-
tified are tobacco and alcohol. These appear to have a syn-
ergistic effect on the mucosal surfaces. Carcinogens
produced by tobacco such as nitrosamines and benz-(a)-
pyrene, produce the types of guanine nucleotide changes
found in the p53 mutations seen in HNSCC. Alcohol
effects are less clear, but may act by being metabolized to
acetaldehyde, which damages DNA and traps glutathione,
which is an important peptide in detoxification of carcin-
ogens. Furthermore, alcohol can also induce cytochrome
p450 enzyme CYP2E1, which is involved in inactivation
of various pro-carcinogens found in alcoholic drinks and
tobacco smoke [5-8]. Indeed, one study has found a 20-
fold increased risk of oral and pharyngeal cancer below
age 46 for heavy smokers, and a 5-fold increase for heavy
drinkers; if there was both heavy drinking and smoking,
this combination led to an almost 50-fold increase in risk
[9].
Cannabis has been postulated to have a role in the patho-
genesis of HNSCC. Smoking cannabis theoretically has
the potential for a contributory role in HNSCC as qualita-
tively, cannabis smoke is fairly similar to tobacco smoke
but actually has a greater concentration of the aromatic
poly-carbon carcinogens found in cigarette smoke. Fur-
thermore, cannabis is usually smoked unfiltered, allowing
a greater concentration of toxin unfettered access to the
mucosal surfaces. However, the vast majority of cannabis
smokers do not smoke anywhere near the intensity and
numbers that ordinary cigarette smokers do on a regular
basis. Only one study of note has so far shown a statisti-
cally significant increased risk of head and neck cancer
[10]. Further careful case-control studies aimed at eluci-
dating this connection have not demonstrated the same
result. Nearly all of the studies have limitations of small
sample size and insufficient statistical power. At present,
the evidence for this postulated risk factor remains equiv-
ocal. If there is a link, it appears to be a small one; and it
will take a large multi-centre study to achieve the statisti-
cal power to demonstrate this.
Diet is another factor implicated in the aetiology of
HNSCC, especially a low consumption of fibre and vita-
mins in the form of fresh fruit and vegetables [11]. Oral
hygiene and the state of dentition have also been linked
to an increased risk of developing oro-pharyngeal cancer.
More than 20 teeth lost, more than 5 defective teeth and
poorly fitting or defective complete dentures were signifi-
cantly associated with an increased risk [12]. These are dif-
ficult factors to separate from high alcohol and tobacco
consumption, as deprived low-income communities tra-
ditionally have high consumption of the main risk factors
and low consumption of a better diet, poor dentition and
oral hygiene.
Human papillomavirus (HPV) as a risk factor
Recent data have now attributed a viral aetiology to a sub-
set of head and neck cancers; the human papillomavirus
(HPV). The first clue to this was suggested in 1983 by a
Finnish team led by Stina Syrjänen, who noted that 40%
of the cancers in their study contained histological and
morphological similarities with HPV-associated lesions
[13]. Since then, growing epidemiological evidence
strongly support a role for HPV in a subset of HNSCC. For
instance, the incidence of HNSCC in the USA has reached
a plateau while strong anti-smoking campaigns have
resulted in a decrease in the number of current smokers
from 42.5% in 1965 to 20.9% in 2005, while the number
of never smokers has risen from 44.0% in 1965 to 57.5%
in 2005. Although certain subsets of HNSCC have fallen
in parallel with the reduction in smoking, rates of oropha-
ryngeal cancers, particularly tongue and tonsillar cancers,
have risen steadily by 2.1% and 3.9% among men and
women respectively, aged 20-44 years from 1973 to 2001
[14,15]. Similar patterns have been noted in Stockholm in
Sweden, for tonsillar cancer which rose 2.8-fold between
1970 and 2002, with a concurrent rise in HPV+ tonsillar
cancer, which rose by 2.9-fold during that time, despite a
decreasing prevalence in smoking [16]. A similar trend
has also been noted in Finland [17].
Several studies indicate that oral HPV infection is likely to
be sexually acquired. D'Souza and colleagues recently
showed in a case-control study [18], that a high (26 or
more) number of lifetime vaginal-sex partners and 6 or
more lifetime oral-sex partners were associated with an
increased risk of HNSCC (OR 3.1 and 3.4 respectively).
An increased risk of HPV-associated HNSCC in female
patients with a history of HPV-associated anogenital can-
cers and their male partners is also consistent with HPV
transmission to the oropharyngeal cavity [19]. Serological
and molecular markers of HPV infection are also associ-
ated with increased risks of HNSCC. Hansson et al [20]
found a strong association between the detection of high-
risk HPV DNA in the oral cavity and oro-pharyngeal carci-
noma (OR 230; CI 45-1200) after adjusting for alcohol
and tobacco usage. A separate, nested case-control study
demonstrated an increased risk of greater than 2-fold for
subsequently developing oral cancer if there was HPV-16
seropositivity [21].
Establishing the evidence for a causal role for HPV in a cer-
tain subset of HNSCC has been compounded by the het-
erogeneity of the tumours and multiple primaryHead & Neck Oncology 2009, 1:36 http://www.headandneckoncology.org/content/1/1/36
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anatomical sites. Since Syrjanen's observations in 1985,
there have been numerous publications studying HPV
DNA detection in HNSCC with rates varying from 0% to
100% of tumours studied. These studies employed differ-
ent detection techniques such as lower sensitivity meth-
ods i.e. in situ hybridisation, Southern Blot hybridisation
or high sensitivity methods such as PCR; different sam-
pling methods such as biopsies, scrapes, brushes, oral
rinses, etc; different storage procedures such as fresh fro-
zen or formalin fixed paraffin embedded samples. It is
clear that that the non-standardisation of these multiple
variables has not brought clarity to the field. Kreimer et al
in 2005 conducted a systematic meta-analysis to review
the available literature in the field and ascertain the world-
wide prevalence of HPV in HNSCC [22]. They analysed 60
eligible studies using PCR detection from 26 countries
which included 5046 cases of squamous cell cancers;
2642 oral cancers, 969 oropharyngeal cancers and 1435
laryngeal cancers. HPV prevalence was 35.6% in oropha-
ryngeal cancers, 23.5% in oral cancers and 24.0% in laryn-
geal cancers. Overall prevalence of HPV in HNSCC was
estimated at 26%. HPV 16 was by far the commonest sub-
type in all types of HPV+ cancers; 86.7% of oropharyn-
geal, 68.2% of oral and 69.2% of laryngeal cancers. HPV
18 was next most common but found in only 1% of
oropharyngeal, 8.0% of oral and 3.9% of laryngeal can-
cers. A more recent meta-analysis by Termine et al 2008,
estimated that from studies utilising only FFPE samples,
the pooled prevalence of HPV detected in these HNSCC
(defined as SCCs originating in the oral, pharyngeal and
laryngeal cavities only) was 34.5% [23].
Insights into the molecular mechanisms of HPV 
carcinogenesis
The dominance of HPV 16 in HPV+ HNSCC (85%-95%)
is even greater than that seen in cervical carcinoma
(approximately 50-60%) of total worldwide cases. This is
likely to reflect a difference in life cycles of the different
HPV subtypes in different mucosal locations, with an
associated difference in mucosal immune responses. The
high-risk subtypes of HPV involved in cervical carcinogen-
esis have been defined [24]. Meta-analyses have shown
that the HPV subtypes associated with HNSCC are
broadly similar (but not identical) with those seen in cer-
vical carcinoma [22,23].
It has been shown that these subtypes (particularly 16) are
able to transform and immortalise cells in vitro. These
effects are predominantly due to the E6 and E7 onco-
genes, which bind and enhance degradation of P53 and
RB tumour suppressor genes respectively. There is evi-
dence that immortalisation of oral keratinocytes and epi-
thelial cells occur quite readily [25,26]. Furthermore, one
study showed that HPV+ HNSCC had mutations in the
promoter/enhancer region that conferred significantly
increased activity and thus could increase the expression
of E6 and E7 in these oral keratinocytes [27]. However, it
is interesting to note that the classically low-risk HPV 6
and 11 subtypes have been found in some tonsillar and
laryngeal carcinomas. It is well known that in the rare
event of benign laryngeal papillomas undergoing malig-
nant transformation, HPV 11 has been most commonly
implicated. HPV 6 and 11 have also been implicated in
malignancies such as Ackerman's tumour (verrucous car-
cinoma of the oral cavity). This is analogous to the finding
of HPV 6 and 11 in Buschke-Lowenstein tumours. It is
clear that in certain rare malignancies, HPV 6 and 11 can
play a role.
Integration of HPV DNA into genomic DNA is a common
event in cervical carcinoma, indeed, the dominant form.
It has been shown that integration usually leads to disrup-
tion and/or deletion of HPV E1 or E2 open reading frame
(ORF), which are important for viral replication and tran-
scription. E2 functions also as a repressor of E6 and E7
and disruption of E2 activity allows increased E6 and E7
expression, thus maintaining the immortalised pheno-
type [28]. Integration of HPV 16 DNA also correlates with
a selective growth advantage and may allow the cancerous
cell to outgrow its rivals, this may be an important step in
the pathway of oncogenesis [29]. However, despite the
dominance of the integrated HPV genome in terms of cer-
vical carcinogenesis, 15-30% of cervical cancer contain
HPV only in the episomal form [30-32]. In some of these
cases, investigators have found deletions in the YY1-bind-
ing sites of the LCR (long control region) of HPV 16 epi-
somal DNA which may allow elevated activity of the E6/
E7 promoter [33,34]. It is clear that the actual molecular
pathway to cervical carcinogenesis is far from homogene-
ous.
The situation in head and neck cancers is less than clear
but heterogeneity and the existence of multiple pathways
to carcinogenesis is highly likely. Koskinen et al (2003)
reported that in their series of head and neck cancers, 61%
were HPV DNA positive. HPV 16 was the dominant sub-
type, and found in 84% of HPV+ cancers. RT-PCR analysis
demonstrated that of the HPV 16+ samples, 48% were
integrated, 35% were episomal and 17% were of both
mixed episomal and integrated forms [35]. Tonsillar car-
cinomas have been reported to have the highest preva-
lence rate of HPV DNA contained within cancerous cells
(51%) of all the forms of head and neck cancers [17]. Mel-
lin et al 2002 reported that all 11 cases of HPV+ tonsillar
carcinomas in their series contained HPVDNA in episo-
mal form [36]. Another study in 1992 reported two HPV
16+ tonsillar carcinomas which contained episomal HPV
DNA, and two HPV 33+ tonsillar carcinomas in which
one was integrated and the other had mixed forms [37]. It
is unclear why tonsillar carcinomas appear to have aHead & Neck Oncology 2009, 1:36 http://www.headandneckoncology.org/content/1/1/36
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higher predominance of episomal HPV DNA than other
types of head and neck cancer. It is likely though, that
these various observations suggest a high heterogeneity
and variation in the oncogenic pathways among these
tumours.
The viral load of HPV in head and neck cancers appear to
vary considerably. Available data suggest that oral cavity
HPV viral load measured by DNA is lower than in the cer-
vix [38]. Tonsillar cancers appear to show a wide variation
in HPV copy numbers. The study from Mellin et al 2002
detected 10 - 15,400 (median of 190) HPV 16 copies per
beta-actin copy from 11 HPV 16+ tumours [36]. Of note
was the fact that the 6 patients with > 190 HPV copies/
Beta-actin had significantly better clinical outcome in
terms of tumour free status and survival rate at the 3 year
mark. The authors concluded that the data suggested that
a higher viral load could be a favourable prognostic indi-
cator. Klussmann et al showed in their study that in 7 HPV
16+ tonsillar carcinomas, the viral load ranged from 6.6 ×
10-4 to 172.4 copies/Beta-globin copy in whole tissue.
Laser microdissection of the samples showed that the HPV
DNA was present in the dissected tumour cells and not in
control tissue. Mean HPV 16 loads in dissected sections
ranged from 6 - 150 copies/Beta-globin copy which was
higher than in the corresponding whole tissue (thus dem-
onstrating a dilution effect) [39]. Koskinen et al reported
that the median copy number of E6 DNA was about
80,000 fold higher in tonsillar cancers as compared to
non-tonsillar head and neck cancers. Furthermore, they
reported that tumours with episomal DNA had larger
tumours than patients with mixed or integrated forms of
viral DNA [35]. This suggests that the higher copy number
of episomal viral DNA was able to induce more rapid
growth, perhaps by higher expression of the viral onco-
genes. Weinberger et al (2006) demonstrated that HPV 16
viral load and p16 expression could be used to classify
head and neck cancers into 3 distinct profiles: Class I,
HPV-, p16 low; Class II, HPV+, p16 low; and Class III,
HPV+, p16 high. Of note, was that Class III tumours had
a significantly increased 5 year survival, increased disease-
free survival rate and decreased local recurrence rate, com-
pared to tumours in the other 2 classes. Median HPV viral
load DNA (copies HPV 16/human genome) was 0.0 cop-
ies, 3.6 copies and 46.0 copies for Classes I, II and III
respectively [40]. These results were consistent with those
from Mellin et al (2002) [36].
Clinical implications of HPV+ Head and neck cancers
Accumulating evidence suggests that HPV+ status is an
important prognostic factor associated with a favourable
outcome in head and neck cancers [36,40-43]. In a recent
prospective multi-centre clinical study (as opposed to the
retrospective studies listed above), data from Maura Gilli-
son's lab demonstrated that patients with HPV+ tumours
had better response rates after induction chemotherapy
(82% vs. 55%), and after chemoradiation treatment (84%
vs. 57%) compared to patients with HPV- tumours. Fur-
thermore, they showed that after a median follow-up of
39.1 months, patients with HPV+ tumours had an
improved overall survival of 33%, and after adjustment
for age, tumour stage and ECOG status, a lower risk of
progression and death from any cause, compared to those
with HPV- tumours [44]. Although larger confirmatory
studies are required, this study provided strong evidence
that HPV+ tumour status was 1) associated with a better
response to current treatment regimes, 2) associated with
a much improved survival rate, and risk of progression,
compared to HPV- tumour status.
The study above supports the available evidence that
HPV+ tumours are a completely distinct epidemiological,
biological and clinical subset of tumours from HPV-
tumours [45]. Molecular evidence identifying differential
gene expression between HPV+ and HPV- tumour groups
support this line of thought [46-48]. Weinberger et al
(2006) demonstrated 3 distinct classes of tumours based
on HPV DNA detection and p16 detection [40]. They also
proposed a biological model of HPV-induced head and
neck cancer based on their findings (Class III). In this
model, high-risk HPV E6 and E7 (predominantly HPV 16)
proteins inactivate p53 and pRB, with subsequent upreg-
ulation of p16. Crucially, the model eliminates the need
for mutational inactivation of p53 and pRB (leaving these
tumour suppressor genes essentially intact). Tobacco and
alcohol-related head and neck cancers would have muta-
tions in p53 and pRB, deleting the activity of these path-
ways. The presence of intact p53 may therefore be one
mechanism whereby removal of HPV E6 and E7 expres-
sion (for instance, by the immune response killing E6/E7
expressing cells) leads to the restoration of apoptotic
pathways rendering the tumour more sensitive to chemo-
radiation treatment. The absence of "field cancerization"
may be another factor leading to a better prognosis for
HPV+ cancers. This term has been used to describe the
presence of early genetic changes in epithelia from which
multiple independent lesions can arise, and is typically
seen in alcohol and tobacco -related tumours. This may
also lead to the better treatment response profiles
reported.
Finally, the better prognosis and treatment responses to
chemotherapy and radiotherapy by HPV+ tumours may
mean that HPV status detection is required to better plan
and individualise patient treatment regimes.
Current treatment options available for head and neck 
cancer
Treatment options for early stage disease
Approximately 30 to 40% of patients present with early
stage I/II disease. These patients in general are treated with
curative intent using either single modality treatmentsHead & Neck Oncology 2009, 1:36 http://www.headandneckoncology.org/content/1/1/36
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using either radiation or surgery alone. Because both
modalities result in similar rates of local control and sur-
vival, the choice of treatment is usually based upon an
assessment of functional outcomes and competing mor-
bidities. When surgery is used as primary treatment, adju-
vant radiotherapy is historically added if there are positive
or close margins, bone erosion or pathologically positive
lymphnodes, although combined radiochemotherapy has
been shown to further improve outcome in some high
risk patients [49].
Although early stage disease is associated with an excellent
prognosis, these patients are still at high risk for recur-
rence and second primary tumours and need close moni-
toring.
Potentially resectable local advanced disease
Treatment goals for patients with resectable locally
advanced disease are to maximize cure while maintaining
functional status through organ preservation. Historically
surgery has been combined with postoperative radiother-
apy, especially when risk factors, such as positive surgical
margins, perineural or lymphovascular involvement,
bone or cartilage invasion, T3/4 or nodal disease (N2-3)
or extracapsular lymph node extension, were present.
However with this approach locoregional control and 5-
year survival was usually below 30%, and therefore com-
bined modality approaches, which included chemother-
apy, were tested in large randomized trials.
Definitive Radiochemotherapy
A nonoperative approach is favored for patients in which
surgery followed by either radiation alone or radiochem-
otherapy may lead to severe functional impairment. The
feasibility of non-surgical approach in this situation was
proven by the RTOG 9111 trial [50]. This study rand-
omized 547 patients with stage III and IV supraglottic or
glottic cancer into one of three arms: radiotherapy alone,
concurrent radiochemotherapy with high dose-cisplatin
or induction chemotherapy with cisplatin and fluorour-
acil followed by radiation. Preservation of the larynx and
local control were best achieved with concurrent chemo-
radiotherapy, which led to an absolute reduction of 43%
in the rate of laryngectomy. Larynectomy-free survival was
better in both chemotherapy-containing arms compared
to radiation alone, but overall survival was not different in
the three treatment arms. This study established concur-
rent chemoradiotherapy as accepted standard for patients
with advanced laryngeal cancer who want to preserve their
larynx. However toxicity remains a significant problem
with this approach, but recent advances in radiation such
as the implementation of intensity-modulated radiation
therapy or fractionation of treatment have been shown to
reduce late toxicity without lowering local control rates or
survival [51,52].
Postoperative Chemoradiotherapy
Patients with oral cavity lesions or those with bone/carti-
lage invasion or gross organ destruction are usually clear
candidates for initial surgery. To improve the limited sur-
vival rates in this patient population, two large phase 3
studies have been performed to determine whether the
addition of cisplatin to radiotherapy improves the out-
come, as compared with radiotherapy alone. Whereas in
RTOG 9501 concurrent chemoradiotherapy only reduced
the risk of loco-regional recurrence without differences in
survival, in EORTC 22931 both progression-free survival
and overall survival were significantly longer in patients
receiving postoperative chemoradiotherapy compared to
radiotherapy alone [49,53]. However, both studies
reported a significant increase in toxicities, such as
mucositis, bone marrow suppression and fibrosis, so that
this aggressive treatment should be reserved for patients
with good performance status and high-risk features, such
as positive surgical margins or extracapsular extension.
Patients with comorbity or low risk features should
receive postoperative radiation alone.
Induction chemotherapy
With combined modality treatment as described above
local control rates have risen, but survival still remains
poor, since distant metastasis have become a major site of
fatal recurrence. Since systemic chemotherapy has been
shown to decrease the risk of distant metastasis, several
study groups tested induction chemotherapy followed by
radiochemotherapy in patients with locally advanced
HNSCC. A meta-analysis showed a 5% survival benefit for
induction chemotherapy using cisplatin and fluorouracil
[54]. Since docetaxel has shown substantial single-agent
activity in the palliative setting, it was evaluated in the
induction regimens in two large randomized multicenter
trials. In the European TAX 323 trial, 358 patients with
unresectable, locally advanced stage III and IV tumours
received either docetaxel, cisplatin and fluorouracil or cis-
platin and fluorouracil for four cycles followed by radio-
therapy alone. Median overall survival (18.6 vs. 14.2
months) and progression-free survival was significantly
longer for the patients who received the taxane-containing
regimen [55]. These data were confirmed by the TAX 324
study, in which induction treatment was followed by con-
current radiochemotherapy instead of radiation alone.
501 patients were randomized to PF versus TPF and the
responding patients received 7 weeks of concurrent chem-
oradiationtherapy with Carboplatin. The median survival
was 70.6 month for the TPF group compared to 30.1
months in the PF group [56]. Because of these results TPF
is the new standard for patients who are treated with
induction chemotherapy, however the most important
question whether induction chemotherapy followed by
radiochemotherapy is better than radiochemotherapyHead & Neck Oncology 2009, 1:36 http://www.headandneckoncology.org/content/1/1/36
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alone remains open until results of ongoing trials address-
ing this problem are available.
Recurrent and distant metastatic disease
Up to 50% of patients who die from HNSCC have locore-
gionally recurrent disease as the sole site of failure. Treat-
ment options for those patients depend on primary
treatment strategies. Patients treated with surgery alone
should receive radiotherapy. Previously irradiated
patients who have potentially resectable recurrence
should undergo resection. If surgical salvage is not feasi-
ble alternatives include additional irradiation or palliative
chemotherapy.
Although chemotherapy is of major palliative benefit in
patients with symptomatic metastatic or incurable recur-
rent disease, impact on survival remains unclear. The aver-
age survival for patients receiving chemotherapy is six to
eight months, which is only slightly more compared to
supportive care alone. Therefore palliative treatment strat-
egies should focus not only on response rates but also on
toxicities and life quality aspects.
Among the most active and commonly used single agents
are cisplatin, 5-FU and taxanes with response rates
between 20 and 40%. Higher response rates can be
reached by chemotherapy doublets, but no standard regi-
men could be established so far. Due to a better toxicity
profile taxanes are promising candidates replacing the
mostly used 5-FU as platin partner in the palliative setting,
A randomized phase III study comparing cisplatin plus
paclitaxel to cisplatin plus infusional 5-FU, showed that
the taxan/platin combination was associated with less
diarrhea, mucositis and myelosuppression and better life
quality for patients [57]. For patients in excellent perform-
ance status chemotherapy triplets using a combination of
platinum/taxane plus either 5-FU or ifsosfamide might be
an option which is generally associated with higher
response rates. However they are also more toxic and
whether survival is better as compared to a doublet is not
proven by a controlled randomized trial.
Therapies targeting Epidermal Growth Factor Receptor
The epidermal growth factor receptor (EGFR), a member
of the ErbB family, has been identified as therapeutic tar-
get for HNSCC and several other malignomas like color-
ectal adenocarcinomas and non-small cell lung cancer.
Evaluation of EGFR-targeted therapies in HNSCC-patients
was based on the observation that EGFR is highly
expressed in many tumours and that EGFR overexpression
was associated with reduced survival in several studies.
For clinical use EGFR can be targeted either by antibodies
recognizing the ligand-binding domain of EGFR or by
EGRF tyrosine kinase inhibitors, which interfere with lig-
and-binding induced signaling events. EGF has multifac-
torial effects hence unless extremely specific any
aborogation of its activity may be associated with signifi-
cant unanticipated deleterious side effects in addition to
an anti-tumour activity hence e.g. associated cardiovascu-
lar co-morbidity with anti-EGFR antibody therapy must
be appreciated.
Anti-EGF-R antibody therapy
Cetuximab, a humanized mouse anti-EGF-R IgG1 mono-
clonal antibody, improved locoregional control and over-
all survival in combination with radiotherapy in locally
advanced tumours [58]. In recurrent or metastatic disease
resistant to platinum-based chemotherapy a randomized
phase III study involving 442 subjects demonstrated a sur-
vival benefit for patients treated with cetuximab in addi-
tion to platinum-based therapy [59]. Median survival
times were 10.1 months for the cetuximab plus chemo-
therapy versus 7.4 months for the study arm with chemo-
therapy alone. With the exception of skin rashes
cetuximab did not add significant toxicities to the stand-
ard treatment, however similar to observations in colorec-
tal cancer one study reported improved survival for
patients who develop rashes in response to cetuximab. Of
note, therapeutic response has not been found to be pos-
itively related to EGR-F protein levels, a phenomenon
which is already known from other malignancies.
Other more humanized anti-EGF-R antibodies such a
panitumumab or zalutumumab are currently being evalu-
ated in phase II/III clinical trials and might evolve as alter-
natives to cetuximab in the future [60].
EFFR-targeted TKIs
Two reversible competitive EGFR-selective TKIs have been
evaluated in metastatic HNSCC with therapeutic response
rates between 4 to 10%. Erlotinib which was first
approved for treatment in lung cancer is currently being
tested in several phase II trials in combination with gem-
citabine or platinum-based chemotherapy. Preliminary
response rates above 20% suggest significant efficacy.
Gefitinib, a second TKI with proven efficacy in patients
with specific subtypes of lung cancer, is currently under
investigation in HNSCC. However phase III trials will be
required to determine whether erlotinib or gefitinib
improves survival compared to standard care.
HER 2 is another member of the ERB family which is ele-
vated in a significant proportion of HNSCC. EGFR and
HER 2 heterodimize to form functional signaling com-
plexes, suggesting that TKIs, which are able to target both,
EGFR and HER 2, may result in enhanced clinical
responses [61]. Lapatinib, licensed for use in HER2-over-
expressing breast cancers, is a dual-specificity, reversible
TKI, which is presently evaluated in patients with recur-Head & Neck Oncology 2009, 1:36 http://www.headandneckoncology.org/content/1/1/36
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rent or metastatic HNSCC. Unfortunately preliminary
results show no significant improvement.
So far EGFR-targeted treatments show significant but lim-
ited response rates. This is likely due to activation of com-
pensatory tumour-survival cell signaling pathways in
response to TKI or antibody treatment. More laboratory
research is needed to understand effects of the therapy as
well as tumour compensatory changes. These changes are
not expected to be uniform across HNSCC patients or
tumours. However, a more detailed molecular characteri-
zation of signaling pathways in HNSCC tumours prior to
therapy and alterations resulting from targeting therapies
might help to define subpopulations of responsive
patients and to define novel targets in the future.
Summary
￿ The incidence of head and neck squamous cell carci-
noma (HNSCC) has been gradually increasing over the
last 3 decades.
￿ Human papillomavirus (HPV) induces a subset of head
and neck carcinomas
￿ Oral HPV infection is likely to be sexually acquired.
￿ HPV+ status is an important prognostic factor associated
with a favourable outcome.
￿ anti-EGFR targeted therapy improves locoregional con-
trol and overall survival in combination with radiother-
apy in locally advanced tumours.
￿ Detailed molecular characterization of signaling path-
ways in HNSCC tumours prior to therapy might help to
define subpopulations of responsive patients
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
PG, MG, JE, HS performed the literature research and
composed the manuscript.
MS, LS, TU, WJ and MBS critically revised the manuscript.
References
1. Parkin DM, Bray F: Chapter 2: The burden of HPV-related can-
cers.  Vaccine 2006, 24(Suppl 3):11-25.
2. Mignogna MD, Fedele S, Lo Russo L: The World Cancer Report
and the burden of oral cancer.  Eur J Cancer Prev 2004,
13(2):139-42.
3. Horner MJ, R L, Krapcho M, Neyman N, Aminou R, Howlader N,
Altekruse SF, Feuer EJ, Huang L, Mariotto A, Miller BA, Lewis DR, Eis-
ner MP, Stinchcomb DG, Edwards BK, eds: SEER Cancer Statistics
Review, 1975-2006.  1975 [http://seer.cancer.gov/csr/1975_2006/].
National Cancer Institute. Bethesda, MD based on November 2008
SEER data submission, posted to the SEER web site, 2009
4. Shah JP, Lydiatt W: Treatment of cancer of the head and neck.
CA Cancer J Clin 1995, 45(6):352-68.
5. Poschl G, Seitz HK: Alcohol and cancer.  Alcohol Alcohol 2004,
39(3):155-65.
6. Burns JE, et al.: Gene mutations and increased levels of p53
protein in human squamous cell carcinomas and their cell
lines.  Br J Cancer 1993, 67(6):1274-84.
7. Chang F, et al.: Frequent mutations of p53 gene in oesophageal
squamous cell carcinomas with and without human papillo-
mavirus (HPV) involvement suggest the dominant role of
environmental carcinogens in oesophageal carcinogenesis.
Br J Cancer 1994, 70(2):346-51.
8. Brennan JA, et al.: Association between cigarette smoking and
mutation of the p53 gene in squamous-cell carcinoma of the
head and neck.  N Engl J Med 1995, 332(11):712-7.
9. Rodriguez T, et al.: Risk factors for oral and pharyngeal cancer
in young adults.  Oral Oncol 2004, 40(2):207-13.
10. Zhang ZF, et al.: Marijuana use and increased risk of squamous
cell carcinoma of the head and neck.  Cancer Epidemiol Biomark-
ers Prev 1999, 8(12):1071-8.
11. Macfarlane GJ, et al.: Alcohol, tobacco, diet and the risk of oral
cancer: a pooled analysis of three case-control studies.  Eur J
Cancer B Oral Oncol 1995, 31B(3):181-7.
12. Rosenquist K, et al.: Oral status, oral infections and some life-
style factors as risk factors for oral and oropharyngeal squa-
mous cell carcinoma. A population-based case-control study
in southern Sweden.  Acta Otolaryngol 2005, 125(12):1327-36.
13. Syrjanen K, et al.:  Morphological and immunohistochemical
evidence suggesting human papillomavirus (HPV) involve-
ment in oral squamous cell carcinogenesis.  Int J Oral Surg 1983,
12(6):418-24.
14. Frisch M, et al.: Changing patterns of tonsillar squamous cell
carcinoma in the United States.  Cancer Causes Control 2000,
11(6):489-95.
15. Shiboski CH, Schmidt BL, Jordan RC: Tongue and tonsil carci-
noma: increasing trends in the U.S. population ages 20-44
years.  Cancer 2005, 103(9):1843-9.
16. Hammarstedt L, et al.: Human papillomavirus as a risk factor for
the increase in incidence of tonsillar cancer.  Int J Cancer 2006,
119(11):2620-3.
17. Syrjanen S: HPV infections and tonsillar carcinoma.  J Clin Pathol
2004, 57(5):449-55.
18. D'Souza G, et al.: Case-control study of human papillomavirus
and oropharyngeal cancer.  N Engl J Med 2007, 356(19):1944-56.
19. Hemminki K, Dong C, Frisch M: Tonsillar and other upper aero-
digestive tract cancers among cervical cancer patients and
their husbands.  Eur J Cancer Prev 2000, 9(6):433-7.
20. Hansson BG, et al.: Strong association between infection with
human papillomavirus and oral and oropharyngeal squa-
mous cell carcinoma: a population-based case-control study
in southern Sweden.  Acta Otolaryngol 2005, 125(12):1337-44.
21. Mork J, et al.: Human papillomavirus infection as a risk factor
for squamous-cell carcinoma of the head and neck.  N Engl J
Med 2001, 344(15):1125-31.
22. Kreimer AR, et al.: Human papillomavirus types in head and
neck squamous cell carcinomas worldwide: a systematic
review.  Cancer Epidemiol Biomarkers Prev 2005, 14(2):467-75.
23. Termine N, et al.: HPV in oral squamous cell carcinoma vs head
and neck squamous cell carcinoma biopsies: a meta-analysis
(1988-2007).  Ann Oncol 2008, 19(10):1681-90.
24. Munoz N, et al.: Epidemiologic classification of human papillo-
mavirus types associated with cervical cancer.  N Engl J Med
2003, 348(6):518-27.
25. Park NH, et al.: Immortalization of normal human oral kerati-
nocytes with type 16 human papillomavirus.  Carcinogenesis
1991, 12(9):1627-31.
26. Oda D, et al.: HPV immortalization of human oral epithelial
cells: a model for carcinogenesis.  Exp Cell Res 1996,
226(1):164-9.
27. Chen Z, et al.: Inhibition of vascular endothelial growth factor-
induced endothelial cell migration by ETS1 antisense oligo-
nucleotides.  Cancer Res 1997, 57(10):2013-9.
28. zur Hausen H: Papillomaviruses in human cancers.  Proc Assoc
Am Physicians 1999, 111(6):581-7.
29. Jeon S, Allen-Hoffmann BL, Lambert PF: Integration of human
papillomavirus type 16 into the human genome correlatesPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Head & Neck Oncology 2009, 1:36 http://www.headandneckoncology.org/content/1/1/36
Page 8 of 8
(page number not for citation purposes)
with a selective growth advantage of cells.  J Virol 1995,
69(5):2989-97.
30. Watts KJ, et al.:  Sequence variation and physical state of
human papillomavirus type 16 cervical cancer isolates from
Australia and New Caledonia.  Int J Cancer 2002, 97(6):868-74.
31. Das BC, et al.: Analysis by polymerase chain reaction of the
physical state of human papillomavirus type 16 DNA in cer-
vical preneoplastic and neoplastic lesions.  J Gen Virol 1992,
73(Pt 9):2327-36.
32. Kalantari M, et al.: Physical state of HPV16 and chromosomal
mapping of the integrated form in cervical carcinomas.  Diagn
Mol Pathol 2001, 10(1):46-54.
33. Watts KJ, et al.: Variable oncogene promoter activity of human
papillomavirus type 16 cervical cancer isolates from Aus-
tralia.  J Clin Microbiol 2001, 39(5):2009-14.
34. Dong XP, et al.: Prevalence of deletions of YY1-binding sites in
episomal HPV 16 DNA from cervical cancers.  Int J Cancer
1994, 58(6):803-8.
35. Koskinen WJ, et al.: Prevalence and physical status of human
papillomavirus in squamous cell carcinomas of the head and
neck.  Int J Cancer 2003, 107(3):401-6.
36. Mellin H, et al.: Human papillomavirus type 16 is episomal and
a high viral load may be correlated to better prognosis in
tonsillar cancer.  Int J Cancer 2002, 102(2):152-8.
37. Snijders PJ, et al.: Human papillomavirus (HPV) type 16 and 33
E6/E7 region transcripts in tonsillar carcinomas can origi-
nate from integrated and episomal HPV DNA.  J Gen Virol
1992, 73(Pt 8):2059-66.
38. Remmerbach TW, et al.: PCR detection of human papillomavi-
rus of the mucosa: comparison between MY09/11 and GP5+/
6+ primer sets.  J Clin Virol 2004, 30(4):302-8.
39. Klussmann JP, et al.: Prevalence, distribution, and viral load of
human papillomavirus 16 DNA in tonsillar carcinomas.  Can-
cer 2001, 92(11):2875-84.
40. Weinberger PM, et al.: Molecular classification identifies a sub-
set of human papillomavirus--associated oropharyngeal can-
cers with favorable prognosis.  J Clin Oncol 2006, 24(5):736-47.
41. Licitra L, et al.: High-risk human papillomavirus affects progno-
sis in patients with surgically treated oropharyngeal squa-
mous cell carcinoma.  J Clin Oncol 2006, 24(36):5630-6.
42. Gillison ML, et al.: Evidence for a causal association between
human papillomavirus and a subset of head and neck can-
cers.  J Natl Cancer Inst 2000, 92(9):709-20.
43. Schwartz SR, et al.: Human papillomavirus infection and sur-
vival in oral squamous cell cancer: a population-based study.
Otolaryngol Head Neck Surg 2001, 125(1):1-9.
44. Fakhry C, et al.: Improved survival of patients with human pap-
illomavirus-positive head and neck squamous cell carcinoma
in a prospective clinical trial.  J Natl Cancer Inst 2008,
100(4):261-9.
45. Gillison ML: Human papillomavirus-associated head and neck
cancer is a distinct epidemiologic, clinical, and molecular
entity.  Semin Oncol 2004, 31(6):744-54.
46. Schlecht NF, et al.: Gene expression profiles in HPV-infected
head and neck cancer.  J Pathol 2007, 213(3):283-93.
47. Slebos RJ, et al.: Gene expression differences associated with
human papillomavirus status in head and neck squamous cell
carcinoma.  Clin Cancer Res 2006, 12(3 Pt 1):701-9.
48. Martinez I, et al.: Identification of differentially expressed genes
in HPV-positive and HPV-negative oropharyngeal squamous
cell carcinomas.  Eur J Cancer 2007, 43(2):415-32.
49. Cooper JS, et al.: Postoperative concurrent radiotherapy and
chemotherapy for high-risk squamous-cell carcinoma of the
head and neck.  N Engl J Med 2004, 350(19):1937-44.
50. Forastiere AA, et al.: Concurrent chemotherapy and radiother-
apy for organ preservation in advanced laryngeal cancer.  N
Engl J Med 2003, 349(22):2091-8.
51. Bourhis J, et al.: Hyperfractionated or accelerated radiother-
apy in head and neck cancer: a meta-analysis.  Lancet 2006,
368(9538):843-54.
52. Lee NY, et al.: A comparison of intensity-modulated radiation
therapy and concomitant boost radiotherapy in the setting
of concurrent chemotherapy for locally advanced oropha-
ryngeal carcinoma.  Int J Radiat Oncol Biol Phys 2006, 66(4):966-74.
53. Bernier J, et al.: Postoperative irradiation with or without con-
comitant chemotherapy for locally advanced head and neck
cancer.  N Engl J Med 2004, 350(19):1945-52.
54. Pignon JP, et al.: Chemotherapy added to locoregional treat-
ment for head and neck squamous-cell carcinoma: three
meta-analyses of updated individual data. MACH-NC Col-
laborative GrouMeta-Analysis of Chemotherapy on Head
and Neck Cancer.  Lancet 2000, 355(9208):949-55.
55. Vermorken JB, et al.: Cisplatin, fluorouracil, and docetaxel in
unresectable head and neck cancer.  N Engl J Med 2007,
357(17):1695-704.
56. Posner MR, et al.:  Cisplatin and fluorouracil alone or with
docetaxel in head and neck cancer.  N Engl J Med 2007,
357(17):1705-15.
57. Gibson MK, et al.: Randomized phase III evaluation of cisplatin
plus fluorouracil versus cisplatin plus paclitaxel in advanced
head and neck cancer (E1395): an intergroup trial of the
Eastern Cooperative Oncology Grou.  J Clin Oncol 2005,
23(15):3562-7.
58. Bonner JA, et al.: Radiotherapy plus cetuximab for squamous-
cell carcinoma of the head and neck.  N Engl J Med 2006,
354(6):567-78.
59. Vermorken JB, et al.: Platinum-based chemotherapy plus cetux-
imab in head and neck cancer.  N Engl J Med 2008,
359(11):1116-27.
60. Egloff AM, Grandis JR: Targeting epidermal growth factor
receptor and SRC pathways in head and neck cancer.  Semin
Oncol 2008, 35(3):286-97.
61. Xia W, et al.: Combination of EGFR, HER-2/neu, and HER-3 is
a stronger predictor for the outcome of oral squamous cell
carcinoma than any individual family members.  Clin Cancer
Res 1999, 5(12):4164-74.